Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF)

08/10/2018
19/10/2026
EU PAS number:
EUPAS25664
Study
Finalised
Study identification

EU PAS number

EUPAS25664

Study ID

44734

Official title and acronym

Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF)

DARWIN EU® study

No

Study countries

Greece

Study description

Multi-center, non-interventional, prospective cohort study aiming to enroll 120 IPF patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Study status

Finalised
Research institutions and networks
No information provided.

Contact details

Georgios Patentalakis

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

BOEHRINGER INGELHEIM ELLAS SA
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable